Inhibrx's INBRX-106 Doubles Response Rate in HNSCC Study, Eyes…

Event summary

INBRX-106 plus pembrolizumab achieved a 48.3% cORR vs. 26.5% for pembrolizumab alone in Phase 2 HNSCC study.
Median PFS was 9.6 months for the combination vs. 4.9 months for pembrolizumab alone.
HPV+ patients showed an 80.0% cORR with the combination vs. 33.3% for pembrolizumab alone.
Inhibrx plans to expand the Phase 2 study by 50 HPV+ patients to support accelerated approval.
Initial results from a Phase 1/2 study in NSCLC are expected by mid-2027.

The big picture

Inhibrx's INBRX-106 represents a significant advancement in OX40 agonism, a field that has struggled with traditional bivalent antibody approaches. The strong Phase 2 results in HNSCC, particularly in HPV+ patients, position the drug as a potential game-changer in immuno-oncology. The company's strategic pivot to explore broader indications and combination therapies could expand its market reach beyond head and neck cancer.

What we're watching

Regulatory Pathway: Whether the expanded Phase 2 study will successfully position INBRX-106 for accelerated approval.
Clinical Expansion: The pace at which Inhibrx can demonstrate INBRX-106's efficacy in other highly immunogenic tumors.
Combination Strategies: How INBRX-106's ability to amplify antigen-driven T-cell responses will impact cancer vaccine combinations.